IBIONasdaqPharmaceutical PreparationsFiscal year ends June 30

iBio, Inc.

Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Aug 28, 2026

$0.76−0.01 (-0.81%)

Close on Oct 19, 2026

Market cap: $110.48M
P/E (TTM): –
Dividend yield: –

Dividends

iBio has not reported a dividend

No dividend per share appears in iBio's annual filings since fiscal 2011.

Where these numbers come from

Parsed from the XBRL in iBio's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-20 reverse split on Nov 29, 2023
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is IBIO.

Operating margin-35141.0% · median -10510.4%

Net margin-33044.0% · median 99.6%

Company	Revenue	Growth
RLYB	$646.00K	-15.1%
IBIO	$100.00K	-75.0%
LNAI	$51.99K	–
IXHL	–	–
AVTX	–	–
SER	–	–

Company

Next earnings (est.): Nov 11, 2026, after close
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: June 30
Employees: 23
Held by institutions: 54.0%
Auditor: GRASSI & Co., CPAs, P.C.
SEC CIK: 1420720

Advertisement
300 × 250